Mike Matson evaluated two earlier negative bits of information along with Thursday's revenue and earnings-per-share miss to conclude that Medtronic's stock, which has held up despite recent market swings, needs to be downgraded to a "hold" from a "buy".
Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest - and investment - in the space.
ReCor Medical has announced that the first patients, 292 total, have been enrolled in its Radiance-HTN study of its Paradise renal denervation device designed to treat hypertension.
After Medtronic‘s (MDT) January announcement it’s halting renal denervation trials and BSX and Covidien following suit, the medical blogosphere erupted, proclaiming the “fall” of renal denervation. It seems to be more than a little premature, considering there are other forms of renal denervation than RF (such as ReCor‘s ultrasound method) and other potential uses than for hypertension. […]
Two top medical device companies turned up the heat on the renal denervation competition. Both Boston Scientific (BSX) and St. Jude Medical (STJ) delivered promising results from studies on their two respective renal denervation technologies at the Transcatheter Cardiovascular Therapeutics conference in San Francisco. Such technology uses radiofrequency ablation on the nerves leading to the […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
UPDATED WITH ANALYST COMMENT Boston Scientific (NYSE:BSX) is jumping on the renal denervation bandwagon. The Natick, Massachusetts, medical device manufacturer announced Thursday that it is buying Caifornia startup Vessix Vascular for an upfront payment of $125 million and the prospect of additional milestone payments between 2013 and 2019 that would make the transaction be […]
St. Jude Medical (NYSE:STJ) announced Tuesday that its renal denervation technology was effective in lowering blood pressure of patients whose hypertension remained stubbornly high despite being on many medications. The EnligHTN technology was effective in that, on average, patients saw their systolic blood pressure lowered 28 mmHg points after 30 days of treatment. The effect was […]